Lupin Ltd Receives Six Observations from U.S. FDA for Nagpur Injectable Facility

Lupin Ltd, a prominent pharmaceutical company, has recently undergone an inspection by the U.S. Food and Drug Administration (FDA) at its injectable facility in Nagpur. The inspection, which took place from September 8 to September 16, 2025, resulted in six observations. The company has committed to addressing these observations and responding to the U.S. FDA within the specified timeframe. Lupin is dedicated to maintaining compliance with Current Good Manufacturing Practice (CGMP) quality standards across all its facilities.